Show Summary Details
Page of

Melanoma Staging and Risk Stratification 

Melanoma Staging and Risk Stratification
Melanoma Staging and Risk Stratification

Prejesh Philips

, Emmanuel Gabriel

, and Alfredo A. Santillan

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 15 July 2020

Melanoma staging has historically been a dynamic and continuously evolving process. It is based on the existing evidence of factors known to impact prognosis as well as deliver guided therapy. Over the last few decades, clinical melanoma-staging systems have incorporated a wide array of radiological and biochemical modalities. Staging systems are essential to clinicians in order to provide prognostic information to patients, develop tailored treatment strategies, and guide the evaluation of clinical trials. Melanoma staging has evolved as more prognostic factors are characterized. This chapter outlines the major developments in melanoma staging and their impact on current staging systems and risk stratification.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.